+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

A prognostic model for development of significant liver fibrosis in HIV-hepatitis C co-infection



A prognostic model for development of significant liver fibrosis in HIV-hepatitis C co-infection



Plos One 12(5): E0176282



Liver fibrosis progresses rapidly in HIV-Hepatitis C virus (HCV) co-infected individuals partially due to heightened inflammation. Immune markers targeting stages of fibrogenesis could aid in prognosis of fibrosis. A case-cohort study was nested in the prospective Canadian Co-infection Cohort (n = 1119). HCV RNA positive individuals without fibrosis, end-stage liver disease or chronic Hepatitis B at baseline (n = 679) were eligible. A random subcohort (n = 236) was selected from those eligible. Pro-fibrogenic markers and Interferon Lambda (IFNL) rs8099917 genotype were measured from first available sample in all fibrosis cases (APRI ≥ 1.5 during follow-up) and the subcohort. We used Cox proportional hazards and compared Model 1 (selected clinical predictors only) to Model 2 (Model 1 plus selected markers) for predicting 3-year risk of liver fibrosis using weighted Harrell's C and Net Reclassification Improvement indices. 113 individuals developed significant liver fibrosis over 1300 person-years (8.63 per 100 person-years 95% CI: 7.08, 10.60). Model 1 (age, sex, current alcohol use, HIV RNA, baseline APRI, HCV genotype) was nested in model 2, which also included IFNL genotype and IL-8, sICAM-1, RANTES, hsCRP, and sCD14. The C indexes (95% CI) for model 1 vs. model 2 were 0.720 (0.649, 0.791) and 0.756 (0.688, 0.825), respectively. Model 2 classified risk more appropriately (overall net reclassification improvement, p<0.05). Including IFNL genotype and inflammatory markers IL-8, sICAM-1, RANTES, hs-CRP, and sCD14 enabled better prediction of the 3-year risk of significant liver fibrosis over clinical predictors alone. Whether this modest improvement in prediction justifies their additional cost requires further cost-benefit analyses.

(PDF emailed within 1 workday: $29.90)

Accession: 059391901

Download citation: RISBibTeXText

PMID: 28467457


Related references

Development and validation of a nomogram based on clinical factors and standard laboratory tests for prediction of clinically significant liver fibrosis in chronic hepatitis C virus infection. European Journal of Gastroenterology and Hepatology 25(12): 1385-1395, 2014

Development of algorithms based on serum markers and transient elastography for detecting significant fibrosis and cirrhosis in chronic hepatitis B patients: Significant reduction in liver biopsy. Hepatology Research 46(13): 1367-1379, 2016

Serum markers of liver fibrosis in patients with chronic hepatitis C infection. Prognostic value of noninvasive markers of fibrosis in liver transplantation. Gastroenterologia Y Hepatologia 35 Suppl 2: 17-22, 2013

Serum NX-DCP as a New Noninvasive Model to Predict Significant Liver Fibrosis in Chronic Hepatitis C. Hepatitis Monthly 15(2): E22978, 2015

A new model using routinely available clinical parameters to predict significant liver fibrosis in chronic hepatitis B. Plos One 6(8): E23077, 2011

Identification of chronic hepatitis B patients without significant liver fibrosis by a simple noninvasive predictive model. American Journal of Gastroenterology 100(3): 616-623, 2005

Prediction of significant liver fibrosis in kidney transplant patients with chronic hepatitis C virus infection: the TX-3 index. Journal of Viral Hepatitis 17(6): 391-399, 2010

HIV-positive men who have sex with men are at high risk of development of significant liver fibrosis after an episode of acute hepatitis C. Journal of Viral Hepatitis 24(10): 832-839, 2017

Establishment and validation of a simple noninvasive model to predict significant liver fibrosis in patients with chronic hepatitis B. Hepatology International 6(1): 360-368, 2012

Prevalence of non-significant liver fibrosis and rate of fibrosis progression in HIV/hepatitis C virus- co-infected patients: still a role for liver biopsy?. Aids 18(12): 1746-1748, 2004

Correlation of liver biochemistry with liver stiffness in chronic hepatitis B and development of a predictive model for liver fibrosis. Liver International 28(10): 1408-1416, 2008

Decreasing hepatitis B viral load is associated with a risk of significant liver fibrosis in hepatitis B e antigen positive chronic hepatitis B. Journal of Medical Virology 86(11): 1828-1837, 2015

Prognostic value of clinical variables and liver histology for development of fibrosis and cirrhosis in autoimmune hepatitis. Scandinavian Journal of Gastroenterology 52(3): 321-327, 2016

Rapid development of advanced liver fibrosis after acquisition of hepatitis C infection during primary HIV infection. Aids Patient Care and Stds 23(6): 403-406, 2009

Hepatic Fibrosis Progression in HIV-Hepatitis C Virus Co-Infection--The Effect of Sex on Risk of Significant Fibrosis Measured by Aspartate-to-Platelet Ratio Index. Plos One 10(6): E0129868, 2016